Terraneo Nastassja, Jacob Francis, Dubrovska Anna, Grünberg Jürgen
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland.
Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Front Oncol. 2020 Mar 17;10:319. doi: 10.3389/fonc.2020.00319. eCollection 2020.
Ovarian cancer (OC) is one of the most lethal gynecologic malignancies. Due to the lack of specific symptoms and screening methods, this disease is usually diagnosed only at an advanced and metastatic stage. The gold-standard treatment for OC patients consists of debulking surgery followed by taxane combined with platinum-based chemotherapy. Most patients show complete clinical remission after first-line therapy, but the majority of them ultimately relapse, developing radio- and chemoresistant tumors. It is now proposed that the cause of recurrence and reduced therapy efficacy is the presence of small populations of cancer stem cells (CSCs). These cells are usually resistant against conventional cancer therapies and for this reason, effective targeted therapies for the complete eradication of CSCs are urgently needed. In this review article, we highlight the mechanisms of CSC therapy resistance, epithelial-to-mesenchymal transition, stemness, and novel therapeutic strategies for ovarian CSCs.
卵巢癌(OC)是最致命的妇科恶性肿瘤之一。由于缺乏特异性症状和筛查方法,这种疾病通常仅在晚期和转移阶段才被诊断出来。OC患者的金标准治疗包括减瘤手术,随后是紫杉烷联合铂类化疗。大多数患者在一线治疗后显示出完全临床缓解,但其中大多数最终会复发,形成对放疗和化疗耐药的肿瘤。现在有人提出,复发和治疗效果降低的原因是存在少量癌症干细胞(CSC)。这些细胞通常对传统癌症疗法具有抗性,因此,迫切需要有效的靶向疗法来彻底根除CSC。在这篇综述文章中,我们重点介绍了CSC治疗耐药性、上皮-间质转化、干性的机制以及针对卵巢CSC的新型治疗策略。